H.C. Wainwright reiterates Arrowhead Pharma stock rating on trial data

Arrowhead Pharmaceuticals’ Phase 3 SHASTA-3/SHASTA-4 topline results show median triglyceride reductions at Month 12 of 79% and 81% vs ~27% on placebo, and a statistically significant reduction in acute pancreatitis events (including a 100% event reduction in high-risk patients). H.C. Wainwright reiterated a Buy rating with a $100 target as the stock jumped 24% over the past week to ~$88.70 near its $95.49 52-week high, with no new safety signals reported. The company plans to file a U.S. supplemental NDA before year-end 2026, framing the readouts as de-risking plozasiran’s expansion into severe hypertriglyceridemia.

Analysis

ARWR is the obvious winner, but the more important read-through is that the company is moving from “interesting platform” to a potentially financeable cardiometabolic asset with enough efficacy to matter in a payer conversation. That de-risks partnering leverage and should support a higher strategic value on the platform, but the commercial winner-take-all story is overstated: the addressable severe-hypertriglyceridemia pool is diagnosis- and adherence-limited, so revenue is more likely to scale in a specialty niche than explode into a primary-care franchise.

The second-order losers are legacy triglyceride therapies and any company depending on inertia in this segment, especially products that compete on convenience rather than event reduction. If prescribers start believing pancreatitis prevention is real, the market may shift from lipid-lowering stack optimization to a narrower high-risk pathway, which helps differentiated injectables but leaves oral maintenance drugs vulnerable to de-emphasis. That said, commercialization will be gated by reimbursement and patient finding, not science; those frictions usually matter more than the headline efficacy print over a 12-18 month horizon.

The key risk is that the stock is now trading ahead of the real catalyst path: filing is far away, so the next 1-3 months are likely about sentiment and analyst model revisions, not earnings inflection. The contrarian view is that the market may be paying too much for a future launch that could still face label narrowing, payer pushback, or slower-than-modeled adoption. A break back below the post-readout gap area would signal the move is being priced as an approval-plus-commercial story rather than a de-risking event, which would be the wrong multiple to pay.

Key Decisions for Investors

• Long ARWR on a 5-10% post-rally pullback, targeting a 3-6 month re-rating into regulatory milestones; risk/reward is better on weakness than chasing after the +24% move.
• For a cleaner expression, buy ARWR Jan-2027 call spreads instead of stock; the thesis is a de-risking over 12-18 months, so options better match the catalyst horizon and cap downside.
• Pair trade: long ARWR / short AMRN for 3-6 months if you want direct exposure to differentiated triglyceride therapy while hedging broad cardiometabolic beta; the winner should be the asset with event-reduction credibility, not just lipid branding.
• Set a tactical alert if ARWR gives back the post-readout gap or if management signals filing slippage; that would be the first sign the market has overcapitalized the data.
• Avoid making this a near-term earnings trade: no position should rely on 2025 P&L impact, since the real monetization window is likely 2027+.